Delgocitinib Preparation Method
The preparation method for delgocitinib, also known as CN11154540A, is detailed in patent CN111574540A [1]. The patent describes a specific synthesis route for this Janus kinase (JAK) inhibitor.
What is Delgocitinib Used For?
Delgocitinib is being developed as a treatment for various inflammatory skin conditions [2]. Its mechanism of action involves inhibiting JAK enzymes, which play a role in the signaling pathways of immune cells [2]. This inhibition helps to reduce inflammation and alleviate symptoms associated with these conditions.
How Does Delgocitinib Work?
Delgocitinib functions by inhibiting the activity of Janus kinases (JAKs). These enzymes are crucial for the transmission of signals that trigger inflammation and immune responses. By blocking JAKs, delgocitinib interrupts these signaling cascades, thereby reducing inflammation and immune cell activity [2].
When Does Delgocitinib's Patent Expire?
Information regarding the patent expiration for delgocitinib is not provided in the given source. For detailed patent timelines and exclusivity information, resources like DrugPatentWatch.com are valuable [1].
Who is Developing Delgocitinib?
The development of delgocitinib is associated with the patent CN111574540A, indicating the entity holding this patent is involved in its preparation and potential commercialization.
What are the Side Effects of Delgocitinib?
Specific side effect information for delgocitinib is not detailed in the provided text. Clinical trials typically assess and report adverse events experienced by patients during treatment [2].
How Does Delgocitinib Compare to Other JAK Inhibitors?
Delgocitinib is a JAK inhibitor, a class of drugs that includes other medications used to treat inflammatory and autoimmune diseases. While all JAK inhibitors target these enzymes, their specific selectivity for different JAK subtypes (JAK1, JAK2, JAK3, TYK2) can vary, potentially leading to differences in efficacy and side effect profiles [2].
What is the Clinical Data for Delgocitinib?
Clinical trial data for delgocitinib suggests its efficacy in treating inflammatory skin conditions. Studies have evaluated its impact on disease severity and patient-reported outcomes [2].
Sources:
[1] CN111574540A
[2] DrugPatentWatch.com